January 30, 2018 / 10:04 PM / 7 months ago

BRIEF-Bellicum Pharmaceuticals Announces Clinical Hold On BPX-501 Clinical Trials In U.S.

Jan 30 (Reuters) - Bellicum Pharmaceuticals Inc:

* BELLICUM PHARMACEUTICALS ANNOUNCES CLINICAL HOLD ON BPX-501 CLINICAL TRIALS IN THE UNITED STATES

* BELLICUM PHARMACEUTICALS INC - ‍RECEIVED NOTICE FROM U.S. FOOD AND DRUG ADMINISTRATION THAT U.S. STUDIES OF BPX-501 HAVE BEEN PLACED ON A CLINICAL HOLD​

* BELLICUM PHARMACEUTICALS INC - ‍FDA CLINICAL HOLD DOES NOT AFFECT ONGOING BP-004 REGISTRATION TRIAL IN EUROPE​

* BELLICUM PHARMACEUTICALS - STUDIES OF BPX-501 PLACED ON CLINICAL HOLD FOLLOWING THREE CASES OF ENCEPHALOPATHY DEEMED AS POSSIBLY RELATED TO BPX-501

* BELLICUM PHARMACEUTICALS INC - BELLICUM IS AWAITING FORMAL COMMUNICATIONS FROM FDA TO DETERMINE REQUIREMENTS FOR RESUMING STUDIES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below